TEVA PACKAGE DESIGN K — 1980472
Application number
1980472
Registration number
TMA1254465
Type(s)
Design
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2019-08-14
Registered
2024-09-09
Registration Expiry Date
2034-09-09
Registered Owner
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a
6944020 Tel Aviv-Jaffa
ISRAEL
Agent
OSLER, HOSKIN & HARCOURT LLP
Suite 320, World Exchange Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9
Documents
Index headings
- TEVA
- V
Vienna information (Code & Description)
- 5.3.11
- Other leaves
- A 5.3.13
- Stylized leaves
- A 5.3.15
- Two to four leaves
- 26.4.2
- Rectangles
- A 26.4.5
- One quadrilateral
- 26.4.12
- Quadrilaterals containing one or more other geometrical figures -- Note: Including quadrilaterals containing bent or straight lines (except 26.4.11).
- A 26.4.15
- Quadrilaterals containing representations of animals or parts of animals' bodies or plants
- A 26.4.18
- Quadrilaterals containing one or more letters
- 26.11.1
- One line or one band
- A 26.11.9
- Oblique lines or bands
- A 26.11.12
- Curved lines or bands (except a 26.11.13)
- 27.3.1
- Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object
- A 27.3.11
- Letters or numerals representing a plant
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations for human use; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations for the treatment of circulatory system diseases and disorders; Pharmaceutical preparations for the treatment of sensory organ disorders; Pharmaceutical preparations for the treatment of urogenital organ disorders; Pharmaceutical preparations for the treatment of peripheral nervous system disorders; Pharmaceutical preparations for the treatment of neurological disorders.
Recordals (known also as Footnotes)
Owner Address Change / Changement d'adresse du propriétaire DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2022-02-28 COMMENTS / COMMENTAIRES: Voir Preuve au dossier/See evidence on File No. 2121983Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2019-08-14 | ||
| Created | 2019-08-15 | ||
| Formalized | 2019-08-19 | ||
| Amendment to Application | 2022-02-28 | Owner Address Change / Voir Preuve au dossier/See evidence on File No. 2121983 | |
| Pre-Assessment Letter Sent | 2022-04-12 | Retired Goods or Services | |
| Search Recorded | 2024-05-10 | ||
| Examiner's First Report | 2024-05-10 | 2024-11-10 | |
| Approved | 2024-05-27 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2024-05-27 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2024-06-19 | Vol.71 Issue 3634 | |
| Registration Pending | 2024-09-09 | ||
| Registered | 2024-09-09 | 2034-09-09 |